--- title: "Royalty Financing, Definition | MedTech Terms" description: "Non-dilutive capital exchanged for a royalty (typically a percentage of revenue) on a defined product or product family, usually with a capped multiple of…" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/royalty-financing#term", "name": "Royalty Financing", "alternateName": [ "Revenue-based financing", "Royalty monetization" ], "description": "Royalty financing provides upfront capital in exchange for a contractual royalty stream, typically a percentage of net product revenue, until a defined cap (commonly 1.5-3x the financed amount) is reached. In MedTech and the adjacent life-sciences market, dedicated royalty funds (Royalty Pharma, HealthCare Royalty Partners, XOMA) underwrite these structures against products with established revenue or imminent launch. The structure is non-dilutive and typically has no equity, board, or governance rights.", "url": "https://medtechterms.com/terms/royalty-financing", "termCode": "royalty-financing", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/royalty-financing#article", "headline": "Royalty Financing", "description": "Non-dilutive capital exchanged for a royalty (typically a percentage of revenue) on a defined product or product family, usually with a capped multiple of invested capital.", "url": "https://medtechterms.com/terms/royalty-financing", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/royalty-financing" }, "about": { "@id": "https://medtechterms.com/terms/royalty-financing#term" }, "articleSection": "Investment & Finance", "inLanguage": "en", "keywords": "Royalty Financing, Revenue-based financing, Royalty monetization, Investment & Finance, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-09", "dateModified": "2026-05-09", "citation": [ { "@type": "CreativeWork", "name": "BIO, Non-Dilutive Funding Resources", "url": "https://www.bio.org/", "publisher": { "@type": "Organization", "name": "BIO" } }, { "@type": "CreativeWork", "name": "SEC EDGAR, Royalty Pharma 10-K filings", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001802768&type=10-K", "publisher": { "@type": "Organization", "name": "SEC EDGAR" } }, { "@type": "CreativeWork", "name": "PitchBook - MedTech Coverage", "url": "https://pitchbook.com/news/articles/topic/healthtech", "publisher": { "@type": "Organization", "name": "PitchBook" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/non-dilutive-funding#term", "name": "Non-Dilutive Funding", "url": "https://medtechterms.com/terms/non-dilutive-funding" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/venture-debt#term", "name": "Venture Debt", "url": "https://medtechterms.com/terms/venture-debt" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/milestone-payment#term", "name": "Milestone Payment", "url": "https://medtechterms.com/terms/milestone-payment" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Investment & Finance", "item": "https://medtechterms.com/terms?cat=Investment%20%26%20Finance" }, { "@type": "ListItem", "position": 4, "name": "Royalty Financing", "item": "https://medtechterms.com/terms/royalty-financing" } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Investment & Finance](/terms?cat=Investment%20%26%20Finance) 6. / 7. Royalty Financing [All terms](/terms) Investment & Finance [Startup Lifecycle](/ecosystems/startup-lifecycle) # Royalty Financing Non-dilutive capital exchanged for a royalty (typically a percentage of revenue) on a defined product or product family, usually with a capped multiple of invested capital. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 9, 2026 ## Definition Royalty financing provides upfront capital in exchange for a contractual royalty stream, typically a percentage of net product revenue, until a defined cap (commonly 1.5-3x the financed amount) is reached. In MedTech and the adjacent life-sciences market, dedicated royalty funds (Royalty Pharma, HealthCare Royalty Partners, XOMA) underwrite these structures against products with established revenue or imminent launch. The structure is non-dilutive and typically has no equity, board, or governance rights. ## What this means in practice Royalty financing is increasingly used by MedTech companies as bridge capital between approval and profitability, or as a partial monetization of a non-core product line. Cost of capital is generally 12-18% IRR equivalent, cheaper than equity but more expensive than [venture debt](/terms/venture-debt). Common pitfalls - • Stacking royalty financing on top of venture debt without modeling combined cash impact at low-revenue scenarios. - • Underestimating reporting and audit obligations to the royalty financier. ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Investment & Finance Milestone Payment Contingent payment triggered by a defined event in a partnership, M&A, or financing. ](/terms/milestone-payment)[ Investment & Finance Non-Dilutive Funding Capital that does not require giving up equity, such as grants or debt. ](/terms/non-dilutive-funding)[ Investment & Finance Venture Debt Loan made to a venture-backed company, usually alongside or after equity. ](/terms/venture-debt) ### More in Investment & Finance · Same category [ Investment & Finance 409A Valuation An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options. ](/terms/409a-valuation)[ Investment & Finance Anti-Dilution Protection Adjustment that protects investors if the company raises a future round at a lower price. ](/terms/anti-dilution)[ Investment & Finance Bridge Round Interim financing between priced rounds, usually convertible. ](/terms/bridge-round)[ Investment & Finance Burn Rate Rate at which a company spends cash, typically expressed monthly. ](/terms/burn-rate) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Startup Lifecycle](/ecosystems/startup-lifecycle) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 BIO· 1 SEC EDGAR· 1 PitchBook· 1 1. [1 BIO, Non-Dilutive Funding Resources Verified BIO · bio.org ](https://www.bio.org/) 2. [2 SEC EDGAR, Royalty Pharma 10-K filings Verified SEC EDGAR · sec.gov ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001802768&type=10-K) 3. [3 PitchBook - MedTech Coverage Verified PitchBook · pitchbook.com ](https://pitchbook.com/news/articles/topic/healthtech) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Diligencing a MedTech cybersecurity posture? Blue Goat Cyber supports investors and acquirers with cybersecurity diligence on connected MedTech assets. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Investment & Finance Sources 3 Updated 5/9/2026 [Compare with another term](/compare?a=royalty-financing) Learn in 60 seconds Card Lesson Quiz Non-dilutive capital exchanged for a royalty (typically a percentage of revenue) on a defined product or product family, usually with a capped multiple of invested capital. - · Royalty financing is increasingly used by MedTech companies as bridge capital between approval and profitability, or as a partial monetization of a non-core product line. - · Cost of capital is generally 12-18% IRR equivalent, cheaper than equity but more expensive than venture debt. - · The structure is non-dilutive and typically has no equity, board, or governance rights. Remember this Watch out: Stacking royalty financing on top of venture debt without modeling combined cash impact at low-revenue scenarios. Related terms - [Non-Dilutive Funding ](/terms/non-dilutive-funding) - [Venture Debt ](/terms/venture-debt) - [Milestone Payment ](/terms/milestone-payment) You may also need Auto-suggested from Investment & Finance and shared keywords. - [Mergers and Acquisitions(M&A) ](/terms/m-and-a) - [Series A / B / C Financing Rounds ](/terms/series-funding) - [Earn-Out ](/terms/earn-out) - [Initial Public Offering(IPO) ](/terms/ipo) - [Limited Partner / General Partner(LP / GP) ](/terms/lp-gp) - [Liquidity Event ](/terms/liquidity-event) [All Investment & Finance terms](/terms?cat=Investment%20%26%20Finance) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)